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Abstract
As the eye ages, certain changes occur that may affect vision. Presbyopia is corrected by the use of reading glasses. 
Cataracts are common and vision can be restored following a reasonably simple operation. Visual loss due to glaucoma can 
be minimised by early detection and treatment, but once vision has been lost it cannot be recovered. Much research is being 
done on the treatment of age-related macular degeneration, but this currently remains the main cause of irreversible loss of 
vision in the elderly. Results of macular hole surgery are improving due to improved surgical techniques and better diagnostic 
equipment (Optical Coherence Tomography). Underlying vascular disease (systemic hypertension, diabetes, atherosclerosis, 
vasculitis) is usually present in patients with retinal artery occlusion, retinal vein occlusion or anterior ischaemic optic 
neuropathy. 
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Introduction
Loss of vision in the elderly can have 
a multitude of causes.  Often the 
remedy is simple, for example pre-
scribing spectacles (as in the case 
of presbyopia) or a reasonably small 
operation (as in the case of cata-
ract) and all that is needed from the 
general practitioner, is to make the 
diagnosis, reassure the patient and 
refer him /her to the eye care practi-
tioner for definitive management.  In 
cases of profound and sudden loss 
of vision, where vascular occlusion 
(retinal artery or vein occlusions and 
anterior ischaemic optic neuropathy) 
is suspected, it is however important 
for the general practitioner to be able 
to recognise the entity and institute 
initial emergency management prior 
to referral. These patients also usu-
ally have some underlying vascular 
disease (systemic hypertension, dia-
betes, atherosclerosis or vasculitis), 
which may need investigating.   Age-
related macular degeneration (AMD) 
remains the main cause of irrevers-
ible loss of vision in the elderly, and 
unfortunately, though there are nu-
merous treatment options available, 
until recently, results of most of these 
have been disappointing.  Success 
of treatment has been measured in 
terms of less loss of vision rather than 
a gain in vision.  Recent advances in 
the treatment of AMD with intraocu-
lar injections are however showing 
promise with many patients regain-
ing some of the vision initially lost. 
Presbyopia
Presbyopia (“farsightedness of ag-
ing”) is the gradual loss of accom-
modative response of the eye, resul-
ting from the loss of lens elasticity. It 
is the most common and one of the 
earlier age-related disorders of the 
eyes. Symptoms of presbyopia usu-
ally begin between the ages of 40 
and 45 years, although they may be-
gin earlier in hyperopes (farsighted 
people) and later in myopes (near-
sighted people).1 Patients notice 
that they need to hold reading mate-
rial further away to read clearly. The 
problem is easily remedied by the 
use of reading glasses (convex or 
“plus” lenses). The rule of thumb for 
Figure 1: Mature cataract
SA Fam Pract 2006:48(7)34 SA Fam Pract 2006:48(7) 35
CPD Article
choosing these glasses is age less 
40 divided by 10. Thus, a fifty-year-
old patient would probably need +1 
dioptre reading glasses.
Cataract 
Age-related cataract is a very com-
mon cause of visual impairment in 
older adults. The prevalence of cata-
racts in people aged between 65 
and 74 years is 50% and it increases 
to 70% in those over the age of 75 
years.2 There are three main types 
of age-related cataracts: nuclear, 
cortical and posterior subcapsular. 
Components of more than one type 
usually are present. 
Nuclear cataract is caused by an 
excessive amount of hardening and 
yellowing of the lens nucleus and 
can be seen as a central black ring 
against the red reflex when exami-
ning the eye with an ophthalmoscope 
with the pupil dilated. It causes grea-
ter impairment of distance rather than 
near vision. Early in the condition, the 
hardening of the lens nucleus leads 
to a change in the refractive index of 
the lens, which in turn leads to a my-
opic shift in refraction. This temporar-
ily enables the presbyopic patient to 
read without reading glasses and is 
sometimes referred to as “second 
sight”. In advanced cases of nuclear 
cataract, the lens nucleus becomes 
opaque and brown and is called a 
brunescent nuclear cataract.
Cortical cataracts start as wedge-
shaped peripheral lens opacities, 
often called “cortical spokes”, which 
are seen as dark shadows against 
the red reflex. The early symptoms 
are glare from intense focal light 
sources such as the headlights of 
oncoming cars and, sometimes, 
monocular diplopia. They enlarge 
and coalesce with time. When the 
entire cortex becomes opaque and 
white, the cataract is said to be ma-
ture (see Figure 1). 
Posterior subcapsular cataracts 
are seen more often in younger pa-
tients. The central posterior pole of 
the lens is affected and near visual 
acuity is more affected than distance 
visual acuity. Patients also complain 
of glare and poor vision under bright 
lighting conditions. A dense central 
opacity is seen against the red re-
flex.
The treatment of cataract entails 
its surgical removal with the implan-
tation of an intraocular lens (IOL) 
(see Figure 2). The modern tech-
nique of small incision, sutureless 
phacoemulsification with foldable 
lens implantation is a safe proce-
dure, performed under local or topi-
cal anaesthesia as ambulatory/day 
case surgery and results in immedi-
ate visual recovery. 
A more recent advance in cataract 
surgery is the implantation of multifo-
cal IOLs, which simulate accommo-
dation by allowing pseudophakic pa-
tients to visualise images at different 
focal distances (near and far).3
Discovering co-existing pathology 
does not preclude the patient from 
having cataract surgery, but may 
necessitate advising the patient on 
a guarded visual prognosis. There is 
some controversy whether cataract 
surgery can hasten the progression 
of some disease processes, such as 
age-related macular degeneration, 
glaucoma and diabetic retinopathy. 
Furthermore, the choice of IOL and 
postoperative management may dif-
fer from routine cases.4
The decision regarding whether or 
not cataract surgery is warranted is 
based not on a specific visual acuity, 
but rather on whether reduced visual 
function substantially interferes with 
a patient’s desired activities. 
Figure 2: IOL in the capsular bag following cataract surgery
Figure 3: Drusen at the posterior pole
Glaucoma 
From the literature from the USA, pri-
mary open angle glaucoma (POAG) 
occurs in 1.3% to 2.1% of the popu-
lation over the age of 40 years and 
the incidence increases to nearly 
15% in the population over 80 years.5 
The figures for South Africa are not 
readily available, but it is known that 
POAG occurs more frequently, has 
an earlier onset and is associated 
with higher intraocular pressures in 
black people than in white people. 
[See article in this issue on glaucoma 
– p46] 
Age-related macular degeneration 
(AMD)
AMD is the leading cause of blind-
ness in patients over the age of 50 
years in the Western world. At least 
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10% of people aged between 65 and 
75 will have lost some central vision 
due to AMD. In those older than 75 
years, 30% will be affected to some 
degree.6 It is more common in Cau-
casians. The earliest clinical mani-
festation of AMD is the appearance 
of small, discrete, slightly elevated, 
yellow-white spots at the posterior 
poles of both fundi, called drusen 
(see Figure 3). They are rarely seen 
before the age of 45, are not uncom-
mon between the ages of 45 and 60 
and are frequently seen thereafter. 
Although many eyes with drusen 
maintain good vision throughout 
life, a significant number of elderly 
patients develop decreased central 
vision due to advanced AMD. Two 
main types of advanced AMD are 
recognised – “dry” or non-exudative 
and “wet” or exudative. 
Dry AMD accounts for approximately 
90% of cases and typically causes 
gradual mild to moderate visual 
impairment over months to years.6 
Clinically it is characterised by 
sharply circumscribed circular areas 
of retinal pigment epithelial (RPE) 
atrophy with varying degrees of cho-
riocapillaris loss at the macula. Later 
on, larger choroidal vessels become 
prominent within the atrophic areas 
and the pre-existing drusen disap-
pear.
Wet AMD is sometimes referred to 
as “neovascular” AMD. Even though 
it is less common than dry AMD, only 
accounting for approximately 10% of 
cases, it accounts for 90% of cases 
of more severe visual loss (visual 
acuity < 6/60).7 New vessels grow 
from the choriocapillaris into the sub-
RPE space and later into the subreti-
nal space. Leakage or haemorrhage 
from these vessels leads to serous 
or haemorrhagic detachment of the 
RPE and/or sensory retina. Initial 
symptoms include metamorphopsia 
(distortion of vision) and blurring 
of central vision. Examination of 
the fundus reveals a grey-green, 
slightly elevated lesion, which is of-
ten accompanied by intraretinal or 
subretinal haemorrhage and/or lipid 
exudation (see Figure 4).
The haemorrhagic episode is 
followed by a gradual organisation 
of the blood and eventually the 
formation of a fibrous disciform scar 
at the fovea (see Figures 5a and 
5b). 
                         
Management
Studies have shown that smokers 
are twice as likely to have AMD than 
are non-smokers.8 It is therefore very 
important to encourage smokers to 
stop smoking. The Age-Related Eye 
Disease Study (AREDS) Research 
Group9 has found that, in patients 
with a high risk of AMD progression 
(those with extensive intermediate 
drusen, or at least one large druse, 
or noncentral geographic atrophy, 
or advanced AMD in one eye), 
there was a statistically significant 
reduction in the development of 
advanced AMD in patients using 
antioxidants and zinc (see Table I). 
Table I: AREDS formulation
*Not to be given to smokers
(Very high dosages not without risk)
Historically, laser photocoagulation 
was the mainstay of treatment.10 
The intense thermal treatment 
attacked the choroidal neovascular 
membranes (CNVMs) and resulted 
Figure 4: Choroidal neovascular mem-
brane with surrounding subretinal haem-
orrhage
Figure 5b: Same patient with bilateral disciform scars a year later
Figure 5a: Right and left fundi with exudative AMD 
Vitamin C 500 mg
Vitamin E 400 IU
Beta Carotene* 15 mg
Zinc 80 mg
Cupric oxide 2 mg
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in retinal death in the treated area. 
Unfortunately, this can only help to 
maintain central vision if the lesion 
is outside the foveal centre and 
most cases of wet AMD present with 
foveal involvement
Beginning in 2001, photodynamic 
therapy (PDT) became the standard 
of care for treatment of most patients 
with wet AMD.11 The treatment uses 
a photosensitive intravenous dye 
that is activated by a low-dose laser. 
This leads to closure of the growing 
blood vessels while selectively spar-
ing the overlying retina. However, it 
is only effective in a small subset of 
CNVMs and, although statistically 
better than natural history, most 
patients still lose visual acuity and 
only a very small percentage regain 
lost sight. 
Most recent advances have 
been in the use of antiangiogenic 
substances to attack the underlying 
mechanisms driving the process. 
These include Macugen, Lucentis, 
Avastin (all given as repeated intra-
vitreal injections), Retaane (admin-
istered as a sub-Tenon’s injection) 
and Squalamine (given intrave-
nously). Thus far, only Macugen has 
obtained FDA approval for use in 
AMD and the visual results compare 
favourably to those of PDT.12,13
Macular hole
Idiopathic macular holes occur 
primarily in women in their sixth to 
eighth decades.14 A full-thickness 
macular hole is visible as a sharply 
demarcated round or ovoid defect 
at the fovea, often associated with 
yellow precipitates on the underlying 
RPE and a narrow rim of subretinal 
fluid (see Figure 6). The incidence of 
bilaterality is estimated to be 25% to 
30%.
* Serial ESR and CRP measurements aid decision on when to discontinue maintenance therapy
Figure 6: Full-thickness macular hole 
with rim of subretinal fluid
Figure 7: Pale swollen disc seen in a 
patient with AION (incidental finding of a 
choroidal naevus indicated by arrow)
Table III: Treatment of arteritic AION
Surgery is considered when the 
vision drops below 6/18. The suc-
cess of the surgery is dependent on 
the size and duration of the hole. 
Anterior ischaemic optic neuropa-
thy (AION)
AION is a relatively common cause 
of severe visual loss in the middle-
aged and elderly. It is the seg-
mental or generalised infarction of 
the anterior part of the optic nerve 
caused by occlusion of the short 
posterior ciliary arteries.15 It can be 
classified as being arteritic or non-
arteritic. Arteritic AION is associated 
with giant cell arteritis (GCA). It is a 
medical emergency, and prevention 
of blindness depends on its prompt 
recognition and treatment (see 
Tables II and III). 
Non-arteritic AION typically occurs 
as an isolated event in patients 
between the ages of 45 and 65 
years, who are either healthy or 
have hypertension as the only sign 
of vascular disease. Visual loss is 
usually less profound than with ar-
teritic AION. Fundus examination of 
both arteritic and non-arteritic AION 
shows a pale swollen disc, often as-
sociated with a few splinter-shaped 
haemorrhages (see Figure 7).
Investigations to exclude GCA 
include: ESR, C-reactive protein 
(CRP) (both high in GCA) and a 
temporal artery biopsy to histologi-





Sudden profound loss of vision
Afferent papillary defect 
Tender, inflamed and nodular 
temporal arteries
Drug & dosage Duration
Methylprednisolone 1 g daily IV plus
Prednisone 80 mg daily orally 3 days
Reduce Prednisone to 60 mg daily orally 4 days
Reduce Prednisone by 5 mg per week to 10 mg daily orally 10 weeks
Prednisone 10 mg daily orally (maintenance)* 1 – 2 years
Retinal vascular occlusions
Retinal vein occlusions mostly affect 
patients in the sixth or seventh de-
cades of life.16 Other predisposing 
diseases include systemic hyper-
tension, diabetes, blood dycrasias, 
raised intraocular pressure, hyper-
metropia and periphlebitis. Patients 
present with a sudden loss of vision, 
often noticed upon waking in the 
morning.
Table II: Symptoms and signs of 
GCA
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On funduscopy one can see dilated 
and tortuous veins, flame-shaped as 
well as dot-blot haemorrhages, cot-
ton-wool spots and retinal oedema 
(see Figure 8). Ischaemic vein oc-
clusions may be complicated by the 
development of new vessels – either 
on the iris (central retinal vein occlu-
sions) or on the retina (branch reti-
nal vein occlusions). These patients 
need monthly reviews for six months 
and, should new vessels develop, 
they need treatment with panretinal 
photocoagulation (laser).
Retinal artery occlusions are usu-
ally caused by emboli from either 
the heart or the carotid arteries. A 
patient with a central retinal artery 
occlusion will present with an acute 
and profound loss of vision and will 
have an afferent pupillary defect. 
The retina appears white as a result 
of cloudy swelling caused by intra-
cellular oedema (see Figure 9). The 
thinner central fovea, devoid of in-
ner retinal layers, contrasts with the 
surrounding opaque retina, giving 
rise to the “cherry-red-spot” appear-
ance. In about 20% of cases, a por-
tion of the papillomacular bundle is 
supplied by one or more cilioretinal 
arterioles from the ciliary circulation 
– in these patients some central vi-
sion may be spared.
The treatment of an arterial occlu-
sion (Table IV) is aimed at restor-
ing retinal circulation as quickly as 
possible. Retinal tissue cannot sur-
vive ischaemia for more than a few 
hours, but because most occlusions 
are not complete it is reasonable to 
treat all cases seen within 48 hours. 
In conclusion
•  Cataracts are the most common 
cause of reversible visual 
loss. Cataract surgery is the 
most cost-effective surgical 
procedure, and the second 
most cost-effective medical 
intervention (after immunisation)
•  Elderly patients must be screened 
for glaucoma to prevent irrevers-
ible painless loss of vision
•  Smokers are twice as likely to 
have advanced age-related 
macular degeneration as non-
smokers
•  Sudden loss of vision in the el-
derly may be caused by giant 
cell arteritis: prompt diagnosis 
and treatment is imperative to 
prevent second eye involvement
•  Most retinal vein occlusions have 
hypertension or diabetes as the 
underlying cause
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Table IV: Emergency treatment of central retinal artery occlusion
Treatment Effect
Intermittent ocular massage for at least 15 minutes Lower IOP, increase blood flow, dislodge embolus
Inhalation of 95%/5% oxygen-carbon dioxide mixture Vasodilatation
Oral acetazolamide Lower IOP
Anterior chamber paracentesis Lower IOP
Figure 8: Retinal haemorrhages and 
cotton-wool spots in a central retinal 
vein occlusion
Figure 9: Central retinal artery oc-
clusion with sparing of the cilioretinal 
artery
